Jump to:

Oxford Drug Design hero image

Oxford Drug Design

Follow

Our aim is to develop breakthrough medicines against cancer and other major diseases with pioneering AI

119%
 - 
Funded 4 Mar 2026
£700,001 target
£837,954 from 344 investors
More
Less

Business overview

Location Oxford, United Kingdom
Social media
Website oxforddrugdesign.com
Sectors Healthcare Mixed Digital/Non-Digital B2B
Company number 04305857
Incorporation date 16 May 2017
More
Less

Investment summary

Type Equity
Valuation (pre-money) £10.4M
Equity offered 7.41%
UK tax relief

EIS

More
Less

Business highlights

  • £13m raised in competitive grants and equity
  • Aim to fight cancer globally with innovative therapy
  • Pioneering Oxford AI technologies
  • Led by experienced professionals Pfizer, Merck,GSK
More
Less

Key features

  • Nominee investment min. £20.40 +
  • Direct investment min. £25,000.00 +

Pitch

About the Campaign

Oxford Drug Design is on a mission to transform treatment for major cancers. Merging pioneering GenAI power with specialised biochemistry, we’re creating the next generation of therapies aimed at 70% of tumors. Preclinical data shows curative results in animals and we are fundraising our path to the clinic.

Market Opportunity

Killing one in six people worldwide, cancer has a drug market of ca. $220bn and growing at 11% p.a. Our novel medicines can address a disregulation present in 70% of tumors having been designed with proprietary, pioneering AI and specialised expertise in the synthetases disease targets

Traction & Key Accomplishments

Our distinctive tech platform integrates pioneering GenAI with disease target expertise with the goal of accelerating advances to more effective, safer therapies.

Having received £13m in competitive grants and equity funding, our drug candidates have achieved successful animal proof-of-principle validation and are progressing towards the clinic, with a goal of out-licensing/sale to pharmaceutical majors as we aim to displace existing treatments.

This same capability is expandable to discover further novel therapies

Use of Funds

The raised funds will support the working capital we require to advance our therapies towards the clinic and monetisation by sale/out-license to pharmaceutical/biotech companies. They will be allocated in equal parts to R&D and overheads, including patents and fixed costs,needed to grow the business

Key Information

Key information investment sheet

Key Investment Information Sheet is available by downloading the following documents:

Share Classes

The company has two classes of shares, Ordinary and Seed Preferred shares. Investment through this campaign is for Ordinary shares, which are EIS eligible.

The Seed Preferred shares carry a 1x participating preference on a liquidation, return of capital or exit.

This means that on a liquidation, return of capital or exit, the proceeds will be distributed as follows:

(1) First, Seed Preferred shares will receive a return equal to the higher of (i) 1x their initial investment back (or, if there are insufficient amounts to do so, an amount pro rata to their investment amount)

(2) Second, Ordinary Shareholders will receive their share of the remaining proceeds pro rata to the number of shares held by them.

(3) Third, surplus proceeds are distributed to all shareholders pro-rata.

Please note, £75,000 of investment reflected in this campaign is receiving Seed Preferred shares.

Outstanding Debt

The company has two outstanding director loans, which are deferred salaries for a total of £44,600.

None of the funds raised in this round will be used to repay these loans.

Investment Multiple

The share price for this round is £0.102. Investors in this round will invest in multiples of £1.02, in batches of 10 shares.

Open an account to get access to the team members of Oxford Drug Design

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for Oxford Drug Design has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 22 January 2026 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £10,405,271

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Republic Europe.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Republic Europe

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Republic Europe campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Nominee investment

This shows if you are able to choose, when making an investment, that you be represented by, and your shareholding be managed by, the Nominee investment.

Find out more

Custodian

If you invest in this Campaign, Republic Europe will act as Custodian rather than provide our standard nominee service. This is due to the fact that the business is not directly involved in the share sale and Republic Europe will not benefit from any rights under a shareholder agreement. As a result, Republic Europe will handle administrative tasks as we do normally, but you will not have information or voting rights, updates from the business, preemption on future fundraising, or ongoing support about business trading activity.

Learn more about Custodian here

Secondary market

This shows if the business has opted-in or opted-out of allowing its shares to be bought and sold on the secondary market.

Find out more

Direct investment

If available, this is an option to invest and hold shares 'directly' in the company (rather than via the Nominee investment). This option is only available to those investing over the threshold amount, which is determined by the fundraising company.

If you choose to hold your shares directly, you will be responsible for any contractual or administrative arrangements with the company you are investing in.

Find out more

Payment options

We are not able to accept card payments for investments into this sector. You can pay for your investment by creating a bank transfer, using funds in your investment account or create a Pay by Bank payment. Your investment will only be completed once the funds have reached our account.

Business Involvement

This Campaign offers shares for sale in business that is not directly involved in this Campaign or the sale. As a result, the Campaign and post-investment experience, including investor rights, will differ from a business-led campaign on Republic Europe. Most notably, the business will not engage with investors in the discussion forums both during and after the sale or provide any updates to investors.

Learn more here

Payment options

We are not able to accept Pay by Bank payments for investments into this sector. You can pay for your investment with a card payment, by creating a bank transfer or by using funds in your investment account. Your investment will only be completed once the funds have reached our account.

Drawdowns

This campaign offers the ability to pay for an investment by drawdowns.

Security Token

A security token is a digital asset that represents ownership or other rights. It is a digital form of traditional investments. In the future, you may be able to trade your investment through compatible exchanges.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Republic Europe.

ContinueCancel